Breaking the Glyco-Code of HIV Persistence and Immunopathogenesis

Overview

Journal Curr HIV/AIDS Rep

Publisher Current Science

Specialty Infectious Diseases

Date 2019 Feb 2

PMID 30707400

Citations 19

Authors

Florent Colomb

Leila B Giron

Irena Trbojevic-Akmacic

Gordan Lauc

Mohamed Abdel-Mohsen

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Glycoimmunology is an emerging field focused on understanding how immune responses are mediated by glycans (carbohydrates) and their interaction with glycan-binding proteins called lectins. How glycans influence immunological functions is increasingly well understood. In a parallel way, in the HIV field, it is increasingly understood how the host immune system controls HIV persistence and immunopathogenesis. However, what has mostly been overlooked, despite its potential for therapeutic applications, is the role that the host glycosylation machinery plays in modulating the persistence and immunopathogenesis of HIV. Here, we will survey four areas in which the links between glycan-lectin interactions and immunology and between immunology and HIV are well described. For each area, we will describe these links and then delineate the opportunities for the HIV field in investigating potential interactions between glycoimmunology and HIV persistence/immunopathogenesis.

Recent Findings: Recent studies show that the human glycome (the repertoire of human glycan structures) plays critical roles in driving or modulating several cellular processes and immunological functions that are central to maintaining HIV infection. Understanding the links between glycoimmunology and HIV infection may create a new paradigm for discovering novel glycan-based therapies that can lead to eradication, functional cure, or improved tolerance of lifelong infection.

Citing Articles

The importance of IgG glycosylation-What did we learn after analyzing over 100,000 individuals.

Kristic J, Lauc G Immunol Rev. 2024; 328(1):143-170.

PMID: 39364834 PMC: 11659926. DOI: 10.1111/imr.13407.

Beyond glycan barriers: non-cognate ligands and protein mimicry approaches to elicit broadly neutralizing antibodies for HIV-1.

Walimbwa S, Maly P, Raskova Kafkova L, Raska M J Biomed Sci. 2024; 31(1):83.

PMID: 39169357 PMC: 11337606. DOI: 10.1186/s12929-024-01073-y.

Circulating immune and plasma biomarkers of time to HIV rebound in HIV controllers treated with vesatolimod.

Abdel-Mohsen M, Deeks S, Giron L, Hong K, Goldman A, Zhang L Front Immunol. 2024; 15:1405348.

PMID: 38979421 PMC: 11229794. DOI: 10.3389/fimmu.2024.1405348.

Immunoglobulin G N-glycan markers of accelerated biological aging during chronic HIV infection.

Giron L, Liu Q, Adeniji O, Yin X, Kannan T, Ding J Nat Commun. 2024; 15(1):3035.

PMID: 38600088 PMC: 11006954. DOI: 10.1038/s41467-024-47279-4.

Resident microbes shape the vaginal epithelial glycan landscape.

Agarwal K, Choudhury B, Robinson L, Morrill S, Bouchibiti Y, Chilin-Fuentes D Sci Transl Med. 2023; 15(724):eabp9599.

PMID: 38019934 PMC: 11419735. DOI: 10.1126/scitranslmed.abp9599.

References

Kim Y, Min K, Wang Z, Kim J, Jacobson O, Huang P . Development of Sialic Acid-coated Nanoparticles for Targeting Cancer and Efficient Evasion of the Immune System. Theranostics. 2017; 7(4):962-973. PMC: 5381258. DOI: 10.7150/thno.19061. View

Franceschi C, Campisi J . Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014; 69 Suppl 1:S4-9. DOI: 10.1093/gerona/glu057. View

Azevedo M, Eriksson S, Mendes N, Serpa J, Figueiredo C, Resende L . Infection by Helicobacter pylori expressing the BabA adhesin is influenced by the secretor phenotype. J Pathol. 2008; 215(3):308-16. DOI: 10.1002/path.2363. View

Chavez L, Calvanese V, Verdin E . HIV Latency Is Established Directly and Early in Both Resting and Activated Primary CD4 T Cells. PLoS Pathog. 2015; 11(6):e1004955. PMC: 4466167. DOI: 10.1371/journal.ppat.1004955. View

Blackwell C, Jonsdottir K, Hanson M, Todd W, Chaudhuri A, Mathew B . Non-secretion of ABO antigens predisposing to infection by Neisseria meningitidis and Streptococcus pneumoniae. Lancet. 1986; 2(8501):284-5. DOI: 10.1016/s0140-6736(86)92103-3. View

Mendez-Huergo S, Blidner A, Rabinovich G . Galectins: emerging regulatory checkpoints linking tumor immunity and angiogenesis. Curr Opin Immunol. 2017; 45:8-15. DOI: 10.1016/j.coi.2016.12.003. View

Alter G, Altfeld M . NK cells in HIV-1 infection: evidence for their role in the control of HIV-1 infection. J Intern Med. 2008; 265(1):29-42. PMC: 2842208. DOI: 10.1111/j.1365-2796.2008.02045.x. View

Spence S, Greene M, Fay F, Hams E, Saunders S, Hamid U . Targeting Siglecs with a sialic acid-decorated nanoparticle abrogates inflammation. Sci Transl Med. 2015; 7(303):303ra140. DOI: 10.1126/scitranslmed.aab3459. View

Brenchley J, Price D, Schacker T, Asher T, Silvestri G, Rao S . Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006; 12(12):1365-71. DOI: 10.1038/nm1511. View

10.

Lewis Z, Totten S, Smilowitz J, Popovic M, Parker E, Lemay D . Maternal fucosyltransferase 2 status affects the gut bifidobacterial communities of breastfed infants. Microbiome. 2015; 3:13. PMC: 4412032. DOI: 10.1186/s40168-015-0071-z. View

11.

Bhiman J, Lynch R . Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System. Curr HIV/AIDS Rep. 2017; 14(2):54-62. PMC: 5401706. DOI: 10.1007/s11904-017-0352-1. View

12.

Erlandson K, Allshouse A, Jankowski C, Lee E, Rufner K, Palmer B . Association of functional impairment with inflammation and immune activation in HIV type 1-infected adults receiving effective antiretroviral therapy. J Infect Dis. 2013; 208(2):249-59. PMC: 3685225. DOI: 10.1093/infdis/jit147. View

13.

Smith D . HIV as an inflammatory disease. J HIV Ther. 2010; 14(3):50-1. View

14.

Kuller L, Tracy R, Belloso W, De Wit S, Drummond F, Lane H . Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008; 5(10):e203. PMC: 2570418. DOI: 10.1371/journal.pmed.0050203. View

15.

Khaitan A, Unutmaz D . Revisiting immune exhaustion during HIV infection. Curr HIV/AIDS Rep. 2010; 8(1):4-11. PMC: 3144861. DOI: 10.1007/s11904-010-0066-0. View

16.

Pantaleo G, Graziosi C, Demarest J, Butini L, Montroni M, Fox C . HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature. 1993; 362(6418):355-8. DOI: 10.1038/362355a0. View

17.

Miles D, Roche H, Martin M, Perren T, Cameron D, Glaspy J . Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist. 2011; 16(8):1092-100. PMC: 3228158. DOI: 10.1634/theoncologist.2010-0307. View

18.

Vallinoto A, Freitas F, Guirelli I, Machado L, Azevedo V, Cayres-Vallinoto I . Characterization of mannose-binding lectin plasma levels and genetic polymorphisms in HIV-1-infected individuals. Rev Soc Bras Med Trop. 2011; 44(1):1-3. DOI: 10.1590/s0037-86822011000100001. View

19.

Marcobal A, Barboza M, Sonnenburg E, Pudlo N, Martens E, Desai P . Bacteroides in the infant gut consume milk oligosaccharides via mucus-utilization pathways. Cell Host Microbe. 2011; 10(5):507-14. PMC: 3227561. DOI: 10.1016/j.chom.2011.10.007. View

20.

Wong J, Hezareh M, Gunthard H, Havlir D, Ignacio C, Spina C . Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997; 278(5341):1291-5. DOI: 10.1126/science.278.5341.1291. View